- Home
- MYO vs ESLA Comparison
MYO vs ESLA Comparison
Compare MYO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- ESLA
- Stock Information
- Founded
- MYO 2004
- ESLA 2021
- Country
- MYO United States
- ESLA United States
- Employees
- MYO N/A
- ESLA N/A
- Industry
- MYO Industrial Specialties
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYO Health Care
- ESLA Health Care
- Exchange
- MYO Nasdaq
- ESLA Nasdaq
- Market Cap
- MYO 44.6M
- ESLA 35.9M
- IPO Year
- MYO 2017
- ESLA N/A
- Fundamental
- Price
- MYO $0.87
- ESLA $1.05
- Analyst Decision
- MYO Strong Buy
- ESLA Strong Buy
- Analyst Count
- MYO 3
- ESLA 1
- Target Price
- MYO $8.17
- ESLA $16.00
- AVG Volume (30 Days)
- MYO 1.5M
- ESLA 25.2K
- Earning Date
- MYO 11-05-2025
- ESLA 08-12-2025
- Dividend Yield
- MYO N/A
- ESLA N/A
- EPS Growth
- MYO N/A
- ESLA N/A
- EPS
- MYO N/A
- ESLA N/A
- Revenue
- MYO $40,760,091.00
- ESLA N/A
- Revenue This Year
- MYO $25.69
- ESLA N/A
- Revenue Next Year
- MYO $23.52
- ESLA N/A
- P/E Ratio
- MYO N/A
- ESLA N/A
- Revenue Growth
- MYO 93.08
- ESLA N/A
- 52 Week Low
- MYO $0.81
- ESLA $0.63
- 52 Week High
- MYO $7.17
- ESLA $1.78
- Technical
- Relative Strength Index (RSI)
- MYO 25.21
- ESLA 61.31
- Support Level
- MYO $0.81
- ESLA $0.99
- Resistance Level
- MYO $1.01
- ESLA $1.08
- Average True Range (ATR)
- MYO 0.07
- ESLA 0.07
- MACD
- MYO 0.02
- ESLA 0.00
- Stochastic Oscillator
- MYO 17.29
- ESLA 76.63
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.